Inhalation therapeutics
Search documents
MannKind Corporation (MNKD) Presents at Morgan Stanley 23rd Annual Global Healthcare
Seeking Alpha· 2025-09-10 23:30
Core Insights - MannKind has undergone significant changes in the past month, indicating a transformation in its business strategy and operations [5]. Company Overview - MannKind has been in operation for 34 years, originally focusing on inhalation therapeutics, particularly in diabetes [5]. - The company has diversified its focus away from diabetes over the last 7 to 8 years, aiming to apply its inhalation technology in areas that can create the most impact for shareholders, patients, and employees [5].
MannKind Corporation (MNKD) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Seeking Alpha· 2025-09-10 23:30
Company Overview - MannKind has been in operation for 34 years, originally focusing on inhalation therapeutics and diabetes [5] - The company has undergone significant changes in the past month, indicating a shift in its strategic direction [5] Strategic Focus - Over the last 7 to 8 years, MannKind has diversified away from its primary focus on diabetes [5] - The company is now concentrating on applying its inhalation technology in areas that can create the most impact for shareholders, patients, and employees [5]